Business
FDA Awards Breakthrough Device Designation to the ReWalk ReBoot Soft Exo-Suit
Soft exoskeleton device for stroke survivors will be for use at home and in the community to help with walking and mobility MARLBOROUGH, Mass., Nov. 04, 2021
About this update from Lifeward Ltd.
[{"type":"text","content":"Soft exoskeleton device for stroke survivors will be for use at home and in the community to help with walking and mobility MARLBOROUGH, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) (\"ReWalk\" or the \"Company\"), a leading global manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced its ReBoot device has been granted designation as a Breakthrough Device by the Food and Drug Administration (FDA). The ReBoot is a lightweight, battery-powered orthotic exo-suit intended to assist ambulatory functions in individuals with reduced ankle function related to neurological injuries, such as stroke. The ReBoot is a customizable personalized device intended for home and community use. It is a sister product to the ReStore device, which received FDA clearance in 2019 for use in the rehabilitation setting. “Breakthrough device designation from the FDA is a critical milestone for the ReBoot, as it provides a more streamlined review pathway that can get this uniquely innovative device to market faster,” said Larry Jasinski, CEO of ReWalk. “The ReBoot will give stroke survivors a device customizable for each individual user, giving them the opportunity for regular assistance at home and in the community. ” The ReBoot works in conjunction with the muscles of the affected leg to assist individuals not only with maintaining safe foot positioning but also with pushing off the ground, which means it may improve their gait. It may also: Facilitate muscle re-education, particularly of plantarflexor function;Prevent/retard disuse atrophy;Maintain or increase joint range of motion;Improve walking speed and endurance independent of the device; andReduce incidence of falls due to poor foot positioning secondary to footdrop. The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. It is available for devices and device-led combination products which are subject to review under a premarket approval application (PMA), premarket notification (510(k)), or De Novo classification request (“De Novo request”). The program is intended to help patients have more timely access to these medical device...